[Analysis of spontaneous comments posted by ecstasy users participating in an online survey].

Rev Panam Salud Publica

Universidade de São Paulo (USP), Instituto de Psicologia, Departamento de Psicologia Experimental, São Paulo, Brazil.

Published: December 2007

Objective: To analyze the contents of spontaneous comments posted by ecstasy users participating in an online survey that constitutes phase one of a harm reduction project (projeto Baladaboa) aimed at users of this drug.

Method: Of the 1,140 individual respondents, 412 posted unprompted comments. These comments were grouped into five categories (irrelevant, drugs, testimonies, survey, and project) and submitted to content analysis. Salutations, irreverent comments, and ideological remarks were considered "Irrelevant." Comments on the causes, effects, and consequences of using ecstasy or other drugs; requests for information on the drug; or comments indicating that information is a crucial issue associated with the use of ecstasy were labeled "Drugs." Personal stories made up the group called "Testimonies." Any comments concerning the questionnaire itself, the formulation of questions, the use of certain criteria, and requests to see survey results were designated "Survey." Comments specifically about the Baladaboa project were categorized as "Project".

Results: Content analysis revealed 915 segments among the 412 comments. The percent distribution of segments among the groups were: irrelevant, 9.8%; drugs, 16.4%; testimonies, 18.1%; survey, 25.1%; and project, 30.6%. Most of the comments concerning the survey and the project were positive.

Conclusions: The number and content of the spontaneous comments indicate that the project, as well as the harm reduction strategy, were being well received by the target audience. The participants expressed their engagement with the project and suggested that its continuation is both timely and urgent.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s1020-49892007001100004DOI Listing

Publication Analysis

Top Keywords

comments
12
spontaneous comments
12
comments posted
8
posted ecstasy
8
ecstasy users
8
users participating
8
participating online
8
harm reduction
8
survey project
8
content analysis
8

Similar Publications

Author's reply: Comment on: "Paediatric-onset autoimmune liver disease: Insights from a monocentric experience".

Dig Liver Dis

January 2025

NEUROFARBA Department, University of Florence, viale Gaetano Pieraccini 6, 50139 Firenze, Italy; Meyer Children's Hospital IRCCS, viale Gaetano Pieraccini 24, 50139 Firenze, Italy.

View Article and Find Full Text PDF

Comment on "Stability and degradation mechanism of (-)-epicatechin in thermal processing".

Food Chem

January 2025

Poznań University of Technology, Institute of Chemistry and Technical Electrochemistry, Berdychowo 4, 60-965 Poznań, Poland. Electronic address:

Catechins, due to their high antioxidant capacity, are ones of the most common ingredients of human diet (e.g. tea, fruits, cacao) of the well-known health benefit properties.

View Article and Find Full Text PDF

Flurpiridaz F 18: First Approval.

Am J Cardiovasc Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!